难治/复发性免疫性血小板减少症的治疗现状与进展

原发性免疫性血小板减少症(immune thrombocytopenia,ITP)是一种免疫介导的获得性血小板减少所致出血性疾病,其患者外周血小板计数＜100×109/L,并且没有引起血小板减少的明显诱因或基础疾病.目前难治性ITP的治疗十分棘手,尚无统一的治疗方案.抑制血小板过度破坏和促进血小板生成是现代ITP治疗的主流思路.其中,促血小板生成药物是近年来治疗难治性ITP的新方向.ITP的发病机制复杂且多样化,如何甄别ITP患者的发病机制并给予针对性的个体化治疗,将是今后关于ITP在临床与科研中的重要方向.

Advances in the treatment of refractory/relapsed immune thrombocytopenia

Primary immune thrombocytopenia（ITP） is an autoimmune disorder defined as immune-mediated acquired thrombocytopenia （platelet count ＜ 100 × 109/L） in the absence of conditions known to cause thrombocytopenia.The treatment of refractory ITP is in a dilemma.The attempts to reduce the platelet destruction and increase platelet production have opened new avenues for the design of specific immunotherapies,among which the thrombopoietin receptor agonists have been tested in several large multicenter clinical trials on ITP and gained promising results.Due to the complicated and diverse pathogenesis of ITP,further explorations on the individualized therapy for the pathogenesis of ITP will be the important goals for the management of ITP.